Survival After Surgical Resection of Stage IV Esophageal Cancer

Slides:

Advertisements

Similar presentations

Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic.

Advertisements

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Photodynamic Laser Therapy for Lesions in the Airway

Elevated Preoperative Hemoglobin A1c Level is Associated With Reduced Long-Term Survival After Coronary Artery Bypass Surgery Michael E. Halkos, MD,

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Outcomes of Sublobar Resection Versus Lobectomy for Stage I Non–Small Cell Lung Cancer: A 13-Year Analysis Amgad El-Sherif, MD, William E. Gooding, MS,

Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.

Masatsugu Hamaji, MD, Stephen D. Cassivi, MD, K

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database Traves D. Crabtree,

Association of Perioperative Fluid Balance and Adverse Surgical Outcomes in Esophageal Cancer and Esophagogastric Junction Cancer Shenhai Wei, MD, PhD,

Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E

Phillips B. Harrington, MD, William W. McAlexander, MD, Ayesha S

Trevor Williams, MD, MPH, Brian C

Christopher W. Seder, MD, Mark S. Allen, MD, Francis C

Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis Andrew J. Graham, MD, MS, Fiona M. Shrive,

Salvage Resections for Recurrent or Persistent Cancer of the Proximal Esophagus After Chemoradiotherapy Colin Schieman, MD, Dennis A. Wigle, MD, PhD,

Increased Time From Neoadjuvant Chemoradiation to Surgery Is Associated With Higher Pathologic Complete Response Rates in Esophageal Cancer Talha Shaikh,

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Esophageal Resection for Cancer of the Esophagus: Long-Term Function and Quality of Life Allison J McLarty, MD, Claude Deschamps, MD, Victor F Trastek,

Elevated Preoperative Hemoglobin A1c Level is Associated With Reduced Long-Term Survival After Coronary Artery Bypass Surgery Michael E. Halkos, MD,

Esophagectomy Outcomes in the Endoscopic Mucosal Resection Era

Jong Ho Cho, MD, Masatsugu Hamaji, MD, Mark S. Allen, MD, Stephen D

K. Robert Shen, MD, Mark S. Allen, MD, Stephen D

A Randomized Controlled Trial of Bupivacaine Through Intracostal Catheters for Pain Management After Thoracotomy Mark S. Allen, MD, Lisa Halgren, RN,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Anthony Lemaire, MD, William R

Elizabeth H. Stephens, MD, PhD, Arlene M. Correa, PhD, Min P

Trevor Williams, MD, MPH, Brian C

Superior sulcus (Pancoast) tumor: experience with 105 patients

Theolyn N. Price, MD, Mark S. Allen, MD, Francis C

John Alfred Carr, MD, Joseph J. Amato, MD, Robert S.D. Higgins, MD

Surgical Resection of Rare Esophageal Cancers

Surgical Considerations for the Management and Resection of Esophageal Gastrointestinal Stromal Tumors Matthew G. Blum, MD, Karl Y. Bilimoria, MD, Jeffrey.

Treatment of Postsurgical Chylothorax

Use of Amiodarone After Major Lung Resection

John Agzarian, MD, MPH, Sue L. Visscher, PhD, Ariel W

Walid K. Abu Saleh, MD, Basel Ramlawi, MD, Oz M

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Variation in Hospital Adoption Rates of Video-Assisted Thoracoscopic Lobectomy for Lung Cancer and the Effect on Outcomes Zaid M. Abdelsattar, MD, MS,

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Matthew J. Bott, MD, Hanghang Wang, BA, William Travis, MD, Gregory J

Basel Ramlawi, MD, Monika J. Leja, MD, Walid K

Surgical Therapy for Bilateral Multiple Primary Lung Cancer

Evolving management and outcome of esophageal cancer with airway involvement E.Pendleton Alexander, MD, Gregory D Trachiotis, MD, Timothy O Lipman, MD,

Jonathan D. Spicer, MD, PhD, Jitesh B. Shewale, BDS, PhD, David B

Phillip G. Rowse, MD, Dawn E

Zaid M. Abdelsattar, MD, MS, K

Specialty Training and Mortality After Esophageal Cancer Resection

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Does Timing of Surgical Procedure After Neoadjuvant Chemoradiation Affect Outcomes in Esophageal Cancer? Williams Tessier, MD, Caroline Gronnier, MD,

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Bullectomy for Symptomatic or Complicated Giant Lung Bullae

Neoadjuvant Chemoradiation Therapy Is Beneficial for Clinical Stage T2 N0 Esophageal Cancer Patients Due to Inaccurate Preoperative Staging Jennifer.

Neoadjuvant and Adjuvant Chemotherapy in Resected Pulmonary Large Cell Neuroendocrine Carcinomas: A Single Institution Experience Inderpal S. Sarkaria,

The American Board of Thoracic Surgery: Update

Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,

The Impact of New Technology on Cardiothoracic Surgical Practice

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Esophagectomy for T1 Esophageal Cancer: Outcomes in 100 Patients and Implications for Endoscopic Therapy Arjun Pennathur, MD, Andrew Farkas, BA, Alyssa.

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer Asad A. Shah, MD, Mark F. Berry, MD, Ching Tzao, MD,

Presentation transcript:

Survival After Surgical Resection of Stage IV Esophageal Cancer Sahar A. Saddoughi, MD, PhD, J. Matthew Reinersman, MD, Yuriy O. Zhukov, MD, James Taswell, PA-C, Kristin Mara, MS, S. William Harmsen, MS, Shanda H. Blackmon, MD, MPH, Stephen D. Cassivi, MD, Francis Nichols, MD, K. Robert Shen, MD, Dennis A. Wigle, MD, PhD, Mark S. Allen, MD The Annals of Thoracic Surgery Volume 103, Issue 1, Pages 261-266 (January 2017) DOI: 10.1016/j.athoracsur.2016.06.070 Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Median overall survival (OS) is 331 days, and 1-year OS is 29%, 2-year OS is 17.8%, and 5-year OS is 6%. (Post-Op = postoperatively.) The Annals of Thoracic Surgery 2017 103, 261-266DOI: (10.1016/j.athoracsur.2016.06.070) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Overall survival is not significantly different between patients where M1 disease was known preoperatively or postoperatively (p = 0.1026) However, the trend suggests that preoperative diagnosis of M1 disease where patients have been treated with neoadjuvant chemoradiation may be associated with increased survival from stage IV esophageal cancer. (M1 = metastasis; Post-op = postoperatively; Pre-op = preoperatively.) The Annals of Thoracic Surgery 2017 103, 261-266DOI: (10.1016/j.athoracsur.2016.06.070) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Low T stage has significant survival advantage. Patients with T1/T2 tumors had a median survival of 846 days, while patients with T3/T4 tumors had a median survival of 226 days (p = 0.0002). (Post-Op = postoperatively.) The Annals of Thoracic Surgery 2017 103, 261-266DOI: (10.1016/j.athoracsur.2016.06.070) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 4 Neoadjuvant therapy has a significant survival advantage for patients with Stage IV esophageal cancer (p = 0.03). (Post-op = postoperatively; Tx = treatment.) The Annals of Thoracic Surgery 2017 103, 261-266DOI: (10.1016/j.athoracsur.2016.06.070) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions